logo
Share SHARE
FONT-SIZE Plus   Neg

Merck KgaA Inks License Agreement With Symphogen On Sym004 - Update

Merck KGaA (MKGAY.PK) said Thursday that an exclusive worldwide license agreement was signed with Copenhagen, Denmark-based Symphogen A/S for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor or EGFR.

As per the agreement, Merck will gain exclusive worldwide rights to develop and commercialize Sym004 and will pay Symphogen 20 million euros upfront. Merck will also make payments to Symphogen for clinical development, regulatory and sales performance milestones. Symphogen will also be eligible for potential royalties on net worldwide sales.

Sym004 is comprised of two antibodies that are designed to block ligand binding, receptor activation and downstream signaling. They are also thought to elicit removal of the EGFR receptors from the cancer cell surface by inducing EGFR internalization and degradation.

Sym004 is currently being evaluated in a Phase I/II trial for the treatment of patients with advanced KRAS wild-type metastatic colorectal cancer or mCRC, who have previously progressed on treatment with standard chemotherapy and a marketed anti-EGFR monoclonal antibody.

Additionally, a single-arm, open-label Phase II trial in patients with squamous cell carcinoma of the head and neck, or SCCHN, who have failed anti-EGFR-based therapy is currently in progress.

Dr. Susan Jane Herbert, Head of Global Business Development and Strategy for the Merck Serono division, said, "Sym004 further strengthens our early development pipeline by adding a product that is thought to act via a proposed synergistic mechanism of action not previously studied, but more specifically, it has the potential to become a key asset complementing our already highly successful Erbitux franchise."

The stock closed up 0.79 percent in Frankfurt on Wednesday at 91.65 euros.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Cable-cutters have now one more reason to do so as live television streaming will be available on YouTube TV in 14 more markets in the U.S. Facebook Chief Operating Officer Sheryl Sandberg has donated nearly $100 million in Facebook shares to charity. This is her second charitable donation within a year. A document was filed on Thursday with the Security and Exchange Commission, which shows that Sandberg transferred shares to a special fund she uses for charitable donations. Ford Motor Co.'s new CEO Jim Hackett has taken a more cautious approach to the automaker's plans for rolling out autonomous vehicles. Ford is currently undertaking a 100-day review of its operations and Hackett indicated at delays to the company's plans to launch a fully-autonomous vehicle by 2021.
comments powered by Disqus
Follow RTT